SSRIs in pregnancy do not affect infant growth
Selective serotonin reuptake inhibitors (SSRIs) taken by a woman during pregnancy do not impact her infant's growth during the first year of life, reports a new small study.
Selective serotonin reuptake inhibitors (SSRIs) taken by a woman during pregnancy do not impact her infant's growth during the first year of life, reports a new small study.
The study, published March 20, 2013, on the website of The American Journal of Psychiatry, shows that infants born to mothers who took SSRIs had similar weights, lengths, and head circumferences over the course of their first year as infants born to women who did not take SSRIs.
For the study, pregnant women were evaluated at weeks 20, 30, and 36 of gestation, and mother-and-infant pairs were assessed at 2, 12, 26, and 52 weeks postpartum. Three nonoverlapping groups of women were defined according to their pregnancy exposures: 1) no SSRI and no depression (N=97), 2) SSRI (N=46), and 3) major depression without SSRI (N=31). Maternal demographic and clinical characteristics and newborn outcomes were compared among exposure groups. Infant weight, length, and head circumference were measured by a physician or physician assistant who was blind to depression and SSRI exposure status at each postpartum time point.
The researchers found that neither antenatal major depression nor SSRI exposure was significantly associated with infant weight, length, or head circumference. In addition, the researchers noted, the interaction of group and prepregnancy body mass index was evaluated, and no significant synergistic effect was identified.
Rising endometriosis rates linked to increased pregnancy complications
May 19th 2024A new study presented at the 2024 ACOG meeting reveals a significant rise in endometriosis among pregnant women over the past 20 years, linking the condition to increased obstetric and neonatal complications.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Impact of antiepileptic medications and sex hormones on maternal and child outcomes in epilepsy
May 16th 2024Paula Emanuela Voinescu, MD, PhD, director of the Women's Epilepsy Program at Brigham and Women's Hospital, talked about the influence of sex hormones on maternal outcomes in pregnant women with epilepsy treated with antiseizure medication.
Read More
Echogenic Mass identified as key predictor for retained products of conception
May 13th 2024Discover how recent findings highlight the significance of echogenic masses in accurately diagnosing post-pregnancy complications, shedding light on effective management strategies and reducing the need for invasive interventions.
Read More
